FindTrial
Sign In

EPREX 40000 UI/ml

DRUG3 trials

Sponsors

University College Dublin, Groupe Francophone Des Myelodysplasies

Conditions

Adult subject (18 years of age older) with low or intermediate-1 IPSS risk MDS with transfusions independent anemiaLow risk myelodysplastic syndrom without RS having failed or being ineligible to Erythroid Stimulating AgentTraumatic Injury

Phase 1

COMBOLA Trial: A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to ESA
RecruitingCTIS2024-515354-24-00
Groupe Francophone Des MyelodysplasiesLow risk myelodysplastic syndrom without RS having failed or being ineligible to Erythroid Stimulating Agent
Start: 2022-05-18Target: 160Updated: 2025-12-23

Phase 3

A randomised, double-blind, placebo-controlled trial of erythropoietin alfa versus placebo in mechanically ventilated critically ill patients following traumatic injury
RecruitingCTIS2023-506081-31-00
University College DublinTraumatic Injury
Start: 2022-03-29Target: 1243Updated: 2025-08-12
GFM-EPO-PRETAR: A randomized trial testing early versus late onset of EPO alfa treatment in lower risk MDS with non RBC transfusion dependent anemia and without del 5q
CompletedCTIS2024-515356-21-00
Groupe Francophone Des MyelodysplasiesAdult subject (18 years of age older) with low or intermediate-1 IPSS risk MDS with transfusions independent anemia
Start: 2018-04-17End: 2024-10-29Target: 124Updated: 2024-09-24